Cue Biopharma, Inc. Operating Expenses
Cue Biopharma, Inc. (CUE) reported Operating Expenses of $95.57 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Cue Biopharma, Inc. operating expenses for the quarter ending 2026-06-30 was $95.57M, a 724.68% increase year-over-year.
- Cue Biopharma, Inc. operating expenses for the quarter ending 2026-03-31 was $11.04M, a 13.22% decline year-over-year.
- Cue Biopharma, Inc. operating expenses for the quarter ending 2025-12-31 was $19.96M, a 78.11% increase year-over-year.
- Cue Biopharma, Inc. operating expenses for the quarter ending 2025-09-30 was $9.74M, a 19.81% decline year-over-year.
- Cue Biopharma, Inc. operating expenses for fiscal 2025 was $54.02M, a 6.36% increase from fiscal 2024.
- Cue Biopharma, Inc. operating expenses for fiscal 2024 was $50.79M, a 11.89% decline from fiscal 2023.
- Cue Biopharma, Inc. operating expenses for fiscal 2023 was $57.64M, a 5.82% increase from fiscal 2022.
- Cue Biopharma, Inc. operating expenses for fiscal 2022 was $54.47M, a 7.13% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $95.57M 10-Q · filed 2026-08-14 | $106.61M 10-Q · filed 2026-08-14 | $126.58M derived: sum of 3 quarters · filed 2026-08-14 | $136.32M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $11.04M 10-Q · filed 2026-05-14 | $31.00M derived: sum of 2 quarters · filed 2026-05-14 | $40.75M derived: sum of 3 quarters · filed 2026-05-14 | $52.34M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $19.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $29.71M derived: sum of 2 quarters · filed 2026-03-16 | $41.30M derived: sum of 3 quarters · filed 2026-08-14 | $54.02M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $9.74M 10-Q · filed 2025-11-12 | $21.33M derived: sum of 2 quarters · filed 2026-08-14 | $34.05M 10-Q · filed 2025-11-12 | $45.26M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $11.59M 10-Q · filed 2026-08-14 | $24.31M 10-Q · filed 2026-08-14 | $35.52M derived: sum of 3 quarters · filed 2026-08-14 | $47.67M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $12.72M 10-Q · filed 2026-05-14 | $23.93M derived: sum of 2 quarters · filed 2026-05-14 | $36.08M derived: sum of 3 quarters · filed 2026-05-14 | $49.12M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $23.36M derived: sum of 2 quarters · filed 2026-03-16 | $36.40M derived: sum of 3 quarters · filed 2026-03-16 | $50.79M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $12.15M 10-Q · filed 2025-11-12 | $25.19M derived: sum of 2 quarters · filed 2025-11-12 | $39.58M 10-Q · filed 2025-11-12 | $55.23M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $13.04M 10-Q · filed 2025-08-12 | $27.43M 10-Q · filed 2025-08-12 | $43.08M derived: sum of 3 quarters · filed 2025-08-12 | $56.60M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $14.38M 10-Q · filed 2025-05-12 | $30.04M derived: sum of 2 quarters · filed 2025-05-12 | $43.56M derived: sum of 3 quarters · filed 2025-05-12 | $58.46M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $15.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $29.17M derived: sum of 2 quarters · filed 2025-03-31 | $44.07M derived: sum of 3 quarters · filed 2025-03-31 | $57.64M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $13.52M 10-Q · filed 2024-11-14 | $28.42M derived: sum of 2 quarters · filed 2024-11-14 | $41.99M 10-Q · filed 2024-11-14 | $57.00M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $14.90M 10-Q · filed 2024-08-14 | $28.47M 10-Q · filed 2024-08-14 | $43.48M derived: sum of 3 quarters · filed 2024-08-14 | $54.58M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $13.57M 10-Q · filed 2024-05-09 | $28.58M derived: sum of 2 quarters · filed 2024-05-09 | $39.68M derived: sum of 3 quarters · filed 2024-05-09 | $52.80M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $26.12M derived: sum of 2 quarters · filed 2024-03-28 | $39.23M derived: sum of 3 quarters · filed 2024-03-28 | $54.47M 10-K · filed 2024-03-28 | $54.47M 10-K · filed 2023-03-21 |
| 2022-09-30 | $11.10M 10-Q · filed 2023-11-03 | $24.21M derived: sum of 2 quarters · filed 2023-11-03 | $39.45M 10-Q · filed 2023-11-03 | $55.60M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $13.12M 10-Q · filed 2023-08-08 | $28.36M 10-Q · filed 2023-08-08 | $44.50M derived: sum of 3 quarters · filed 2023-08-08 | $59.91M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $15.24M 10-Q · filed 2023-05-09 | $31.39M derived: sum of 2 quarters · filed 2023-05-09 | $46.80M derived: sum of 3 quarters · filed 2023-05-09 | $59.84M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $16.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $31.56M derived: sum of 2 quarters · filed 2023-03-21 | $44.60M derived: sum of 3 quarters · filed 2023-03-21 | $58.65M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $15.41M 10-Q · filed 2022-11-14 | $28.45M derived: sum of 2 quarters · filed 2022-11-14 | $42.51M 10-Q · filed 2022-11-14 | $53.98M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $13.04M 10-Q · filed 2022-08-04 | $27.11M 10-Q · filed 2022-08-04 | $38.56M derived: sum of 3 quarters · filed 2022-08-04 | $49.40M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $14.07M 10-Q · filed 2022-05-10 | $25.52M derived: sum of 2 quarters · filed 2022-05-10 | $36.36M derived: sum of 3 quarters · filed 2022-05-10 | $48.37M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $11.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $22.28M derived: sum of 2 quarters · filed 2022-03-16 | $34.30M derived: sum of 3 quarters · filed 2022-03-16 | $48.20M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $10.84M 10-Q · filed 2021-11-09 | $22.85M derived: sum of 2 quarters · filed 2021-11-09 | $36.75M 10-Q · filed 2021-11-09 | $46.81M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $12.02M 10-Q · filed 2021-08-09 | $25.91M 10-Q · filed 2021-08-09 | $35.98M derived: sum of 3 quarters · filed 2021-08-09 | $44.05M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $13.89M 10-Q · filed 2021-05-10 | $23.96M derived: sum of 2 quarters · filed 2021-05-10 | $32.04M derived: sum of 3 quarters · filed 2021-05-10 | $42.32M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $10.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $18.14M derived: sum of 2 quarters · filed 2021-03-09 | $28.43M derived: sum of 3 quarters · filed 2021-03-09 | $40.23M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $8.08M 10-Q · filed 2020-11-09 | $18.36M derived: sum of 2 quarters · filed 2020-11-09 | $30.16M 10-Q · filed 2020-11-09 | $41.46M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $10.29M 10-Q · filed 2020-08-07 | $22.08M 10-Q · filed 2020-08-07 | $33.38M derived: sum of 3 quarters · filed 2020-08-07 | $46.59M derived: sum of 4 quarters · filed 2020-08-07 | |
| 2019-03-31 | $11.80M 10-Q · filed 2020-05-07 | $23.09M derived: sum of 2 quarters · filed 2020-05-07 | $36.30M derived: sum of 3 quarters · filed 2020-05-07 | $43.95M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $11.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $24.51M derived: sum of 2 quarters · filed 2020-03-12 | $32.15M derived: sum of 3 quarters · filed 2020-03-12 | $39.84M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $13.21M 10-Q · filed 2019-11-07 | $20.85M derived: sum of 2 quarters · filed 2019-11-07 | $28.54M 10-Q · filed 2019-11-07 | $38.81M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $7.64M 10-Q · filed 2019-08-08 | $15.34M 10-Q · filed 2019-08-08 | $25.60M derived: sum of 3 quarters · filed 2019-08-08 | $30.64M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $7.52M 10-Q · filed 2019-05-08 | $17.96M derived: sum of 2 quarters · filed 2019-05-08 | $22.99M derived: sum of 3 quarters · filed 2019-05-08 | $27.41M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $10.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $15.47M derived: sum of 2 quarters · filed 2019-03-14 | $19.88M derived: sum of 3 quarters · filed 2019-03-14 | $23.23M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $5.03M 10-Q · filed 2018-11-13 | $9.45M derived: sum of 2 quarters · filed 2018-11-13 | $12.79M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $4.41M 10-Q · filed 2018-08-13 | $7.76M 10-Q · filed 2018-08-13 | |||
| 2017-03-31 | $3.35M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |